ClinicalTrials.gg
CompletedNCT04603859WINDOWUpdated Oct 20, 2026

When to INDuce for OverWeight? (WINDOW)

An interventional study of Elective induction of labor at 39 gestational weeks and 0 to 3 days in Pregnancy, Obesity and Parturition, sponsored by University of Aarhus. Completed at 12 sites in Denmark. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment

How we know

Updated Oct 20, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,901
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Obesity by University of Aarhus — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University of Aarhus.

Enrollment
Largest of 26
1,901 · median 30
Started
2020
with 3 others
No phase
24 of 40
3 open now
Registered
25th of 40
by date

Among the 40 studies in Obesity by University of Aarhus, this one has the largest enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2020, is one of 24 with no phase, and was the 25th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 40 studies in Obesity by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Obesity by University of Aarhus, or all of them as a file.
02

Study summary

The rate of overweight and obese women becoming pregnant is increasing. Obesity in pregnancy along with delivery by cesarean section in obese women is associated with several complications as compared to normal weight women. The longer the woman is pregnant, the longer she is at risk. In an otherwise low-risk pregnant woman at term, it is an ongoing clinical dilemma, whether the benefits of elective induction of labor and termination of the pregnancy will outweigh the potential harms from concomitant induction and delivery process. The proposed study is a randomized controlled study of elective induction versus expectant management in obese women. The study will be carried out as a national multicenter study with inclusion of 1900 participants from Danish delivery wards. The null hypothesis is that the caesarean section rate is similar with elective induction of labor at 39 weeks of gestation, compared with expectant management among pregnant women with pre- or early pregnancy BMI≥30.

Read the detailed description

Background The World Health Organization (WHO) defines overweight as a body mass index (BMI) of ≥25 kg/m2 and obesity as a BMI of ≥30 kg/m2. Overweight and obesity are rising dramatically worldwide. In fertile women, the prevalence of obesity is one third in the United States, 20% in the United Kingdom, and 12-13% in Denmark. The association between obesity in pregnancy and the risk of gestational complications increases with increasing BMI. Among other complications, obesity in pregnancy is associated with increased risk of caesarean delivery. Delivery by caesarean section further adds significant risks of wound infection or other infectious morbidity in obese women as compared to normal weight women. The longer the woman is pregnant, the longer the risk of pregnancy complications remains. In an otherwise low-risk pregnant woman at term, it is an on-going clinical dilemma, whether the benefits of elective induction of labor (eIOL) and termination of the pregnancy will outweigh the potential harms from the concomitant induction and delivery process. Regarding delivery complications, based on data from historical cohorts, eIOL has traditionally been associated with an increased risk of caesarean section and instrumental delivery. Therefore, expectant management has been the preferred clinical option. This interpretation has now been challenged by a randomized trial (ARRIVE) with >6000 low-risk pregnant women where eIOL at 39 weeks of gestation was associated with lower caesarean delivery rates. There are no randomized studies in obese women, but two larger observational studies did find lower odds of caesarean delivery in obese women with eIOL as compared to awaiting labor onset. Hence, a randomized trial that would compare caesarean delivery among obese women whose labor is induced with those expectantly managed is warranted. The proposed study will provide new and important knowledge into the area of induction of labor among overweight and obese women with potential great international impact for the future raising number of pregnant women in this subgroup.

With this trial, the investigators aim to compare the risk of caesarean section in obese (BMI ≥ 30 kg/m2), but otherwise low-risk women with eIOL as compared to expectant management.

Materials and methods

The study is a multicenter randomized controlled trial with an allocation ratio of 1:1 in the two following arms:

  • Intervention arm/elective induction of labor in pregnancy at 39 gestational week and 0 to 3 days: Induction is performed according to local policy for induction of labor.
  • Comparison arm/expectant management: Waiting for spontaneous onset of labor unless a situation develops necessitating either induction of labor or caesarean section.

    1900 low-risk pregnant women with a pre- or early pregnancy BMI ≥ 30 carrying a singleton pregnancy will be recruited from the Danish delivery wards. In each trial site, a physician investigator will be responsible for the enrolment, the electronically randomization, and data collection.

The primary endpoint is the caesarean section rate. Among others there will be secondary endpoints on instrumental delivery, onset of labor, methods of induction, perinatal and postpartum complications both maternal and neonatal along with data on women's experience on birth measured by a questionnaire survey four to six weeks post-partum.

Ethics The study will be conducted in accordance with the ethical principles outlined in the latest version of the 'Declaration of Helsinki' and the 'Guideline for Good Clinical Practice' related to experiments on humans. The Central Denmark Region Committee on Biomedical Research Ethics, and The Danish Health Authorities have approved the study.

Perspectives In perspective, more than 39% of the world's population is overweight and 13% are obese by the WHO classification. Pregnant overweight women are at increased risk of pregnancy and delivery complications, and there is a need to improve maternity care for this subgroup of women. The results of this trial have the potential to generate important knowledge for the improvement of delivery in obese women and they will add key information to an on-going discussion of the effects of labor induction before term. Any possible harm or disadvantage to the individual study participant is outweighed by the possible benefit to the increasing number of obese women who will be pregnant in the future.

03

Conditions studied

  • Pregnancy
  • Obesity
  • Parturition

Browse trials for

Keywords

  • Induction of labor
  • Expectant management
  • Cesarean section
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women with pre- or early pregnancy ≥ 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Legal or ethical considerations: maternal age \<18 years, language difficulties requiring an interpreter or translator
  • Multiple pregnancy
  • Previous caesarean section
  • Uncertain gestational age, defined as gestational age determined by other measurements than the Crown-Rump length (CRL) Measurement
  • Planned elective caesarean section at time of randomisation
  • Fetal to IOL at time of randomisation: e.g. non-cephalic presentation, or other fetal conditions contraindicating vaginal delivery
  • Fetal contraindications to expectant management at time of randomisation
  • Maternal contraindications to IOL at time of randomisation: e.g. placenta previa/accreta, vasa previa
  • Maternal contraindications to expectant management at time of randomisation: e.g. maternal medical conditions, ultrasonically diagnosed oligohydramnios (DVP\< 2 cm), signs of labour including pre-labour rupture of membranes (PROM)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,901 participants (actual)

Study arms

  • Experimental
    Elective induction of labour

    Elective induction of labour at 39 gestational weeks and 0 to 3 days.

    Procedure: Elective induction of labor at 39 gestational weeks and 0 to 3 days

  • No intervention
    Expectant management

    Awaiting spontaneous labor.

Interventions

  • ProcedureElective induction of labor at 39 gestational weeks and 0 to 3 days

    Elective induction of labor (eIOL) according to local policies

    Also known as: eIOL

06

What researchers measure

Primary outcomes

  1. Caesarean section

    number (no.)

    Time frame: At delivery

Secondary outcomes

  1. Mode of delivery if not by caesarean

    * Vaginal delivery - no. * Vaginal assisted delivery - no.

    Time frame: At delivery

  2. Mode of delivery

    * Caesarean section - percent * Vaginal delivery - percent * Vaginal assisted delivery - percent

    Time frame: At delivery

  3. Vaginal assisted delivery

    * Forceps - no. * Ventouse - no.

    Time frame: At delivery

  4. Indication for caesarean section (more than one indication is possible)

    * Labour dystocia - no. * Fetal distress - no. * Maternal request - no. * Suspected macrosomia - no. * Non-cephalic presentation - no. * Extensive vaginal bleeding - no. * Suspected uterine rupture - no. * Maternal or fetal complication/condition (free text) - no. * Other indication for caesarean section (free text) - no.

    Time frame: At delivery

  5. Indication for vaginal assisted delivery (more than one is possible)

    * Labour dystocia - no. * Fetal distress - no. * Maternal request - no. * Other indication for assisted vaginal delivery (free text) - no.

    Time frame: At delivery

  6. Use of epidural

    no.

    Time frame: At delivery

  7. Damage to internal organs (bladder, bowel or ureters)

    no.

    Time frame: At delivery to 30 days postpartum

  8. Uterine scar dehiscense or rupture

    no.

    Time frame: At delivery

  9. Complications

    * Minor shoulder dystocia defined as the need for McRobert's maneuver - no. * Major shoulder dystocia defined as the need for procedures other than McRobert's maneuver - no. * Clinical suspicion of abruption of the placenta leading to an intervention in labour - no. * Cord prolapse - no. * Maternal fever defined as temperature \>38,2 / \>38,0 degrees celsius with / without epidural - no. * Perineal 3rd degree laceration - no. * Perineal 4th degree laceration - no. * Episiotomy - no.

    Time frame: At delivery

  10. Postpartum haemorrhage

    * Blood loss \>500ml - no. * Blood loss \>1000ml - no. * Blood transfusion - no. Time Frame \[0-2 days postpartum\]

    Time frame: 0-2 hours postpartum

  11. Hysterectomy

    no.

    Time frame: At delivery to 30 days postpartum

  12. Postpartum morbidity

    * Puerperal infection treated in hospital - no. * Other severe postpartum conditions treated in hospital (free text) - no.

    Time frame: 0-30 days postpartum

  13. Maternal admission to Intensive Care Unit

    no.

    Time frame: Enrollment to 30 days postpartum

  14. Maternal cardiopulmonary arrest

    no.

    Time frame: Enrollment to 30 days postpartum

  15. Maternal death

    no.

    Time frame: Enrollment to 30 days postpartum

  16. Primary neonatal composite including any of the following;

    * Perinatal death (stillbirth and neonatal) * The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame \[within 72 hours after birth\] * Apgar score \< 4 at 5 minutes * Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia) * Seizures * Infection (defined as antibiotic treatment continuously for 7 days minimum) * Meconium aspiration syndrome * Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) * Intracranial or subgaleal hemorrhage * Hypotension requiring vasopressor support

    Time frame: Enrollment to 28 days of life

  17. Components of the primary neonatal composite will additionally be reported separately

    * Perinatal death (stillbirth and neonatal) - no. * The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame \[within 72 hours after birth\] - no. * Apgar score \< 4 at 5 minutes - no. * Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia) - no. * Seizures - no. * Infection (defined as antibiotic treatment continuously for 7 days minimum) - no. * Meconium aspiration syndrome - no. * Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) - no. * Intracranial or subgaleal hemorrhage - no. * Hypotension requiring vasopressor support - no.

    Time frame: Enrollment to 28 days of life

  18. Neonatal trauma composite including any of the following;

    * Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) * Intracranial or subgaleal hemorrhage

    Time frame: At delivery to 28 days of life

  19. Neonatal asphyxia composite including any of the following;

    * Apgar score \< 4 at 5 minutes * Umbilical cord pH-value \< 7.0 (allow missing data) * Umbilical cord standard base excess (sBE) \< -15.0 mmol/l (allow missing data) * Seizures * Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia)

    Time frame: At delivery to 28 days of life

  20. Apgar score at 5 minutes

    * Apgar score \<4 - no. * Apgar score of 4-7 - no.

    Time frame: 5 minutes of life

  21. Umbilical cord arterial and venous blood sample (allow missing data)

    * pH-value \< 7.0 - no. * sBE \< -15.0 mmol/l - no.

    Time frame: 0-30 minutes of life

  22. Neonatal admission

    no.

    Time frame: 0-72 hours of life

  23. Respiratory support during neonatal admission

    * CPAP (y/n) - no. * HNFC (y/n) - no. * Oxygen supplement treatment (y/n) - no. * Ventilator treatment (y/n) - no.

    Time frame: 0-28 days of life

  24. Other treatment during neonatal admission

    * Therapeutic hypothermia (y/n) - no. * Vasopressor support (y/n) - no. * Antibiotic treatment continuously for 7 days minimum (y/n) - no.

    Time frame: 0-28 days of life

Other outcomes

  1. Neonatal characteristics 1

    * Female sex - no. * Birth weight \> 4500 grams (y/n) - no.

    Time frame: At delivery

  2. Neonatal characteristics 2

    \- Mean birth weight - grams

    Time frame: At delivery

  3. Maternal experience on birth

    Childbirth Experience Questionnaire Scoring range is 1 to 4 where higher ratings reflect more positive experiences

    Time frame: 4-6 weeks postpartum

  4. Maternal postnatal depression

    * Major Depression Inventory (MDI) * Edinburgh Postnatal Depression Score Scoring range is 1 to 4 where higher ratings reflect more positive experiences

    Time frame: 4-6 weeks postpartum

07

Study locations

12 sites
  • Aarhus University Hospital
    Aarhus, Denmark
  • Rigshospitalet Juliane Marie Centre
    Copenhagen, Denmark
  • Herlev Hospital
    Herlev, Denmark
  • Gødstrup Regional Hospital
    Herning, Denmark
  • North Zealand's Hospital
    Hillerød, Denmark
  • Hvidovre Hospital
    Hvidovre, Denmark
  • Kolding Hospital
    Kolding, Denmark
  • Nykøbing Falster Hospital
    Nykøbing Falster, Denmark
  • Odense University Hospital
    Odense, Denmark
  • Randers Regional Hospital
    Randers, Denmark
  • Zealand University Hospital
    Roskilde, Denmark
  • Viborg Hospital
    Viborg, Denmark
08

References and documents

Publications

  • Krogh LQ, Boie S, Henriksen TB, Thornton J, Fuglsang J, Glavind J. Induction of labour at 39 weeks versus expectant management in low-risk obese women: study protocol for a randomised controlled study. BMJ Open. 2022 Apr 25;12(4):e057688. doi: 10.1136/bmjopen-2021-057688. PubMed 35470194 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The final dataset will be publicly available in an anonymised form using an open data repository (i.e. CERN) or another equivalent database. All relevant trial-related documents will be shared along with the data.

Time frame: Beginning three months and ending three years after the publication of the last trial results.

Access criteria: Data will be available for any research purpose to all interested parties who have approval from an independent review committee. Interested parties will be able to request the data by contacting the trial sponsor. Authorship of publications emerging from the shared data will follow standard authorship guidelines and will include authors from the WINDOW study group depending on the nature of their involvement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jul 2026, 68 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 68 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2020
First posted
Oct 27, 2020
StartActual
Oct 19, 2020
Primary completionActual
Jul 10, 2026
CompletionActual
Jul 29, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 20, 2026
Enrollment
1900 (estimated)→1901 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Completed
    Enrollment 1900 (estimated)→1901 (actual)
    + 4 other changes: verification date, date precision, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04603859
Collaborators
Aarhus University Hospital, Randers Regional Hospital, Herning Hospital, Central Jutland Regional Hospital, Nykøbing Falster County Hospital, Odense University Hospital, Rigshospitalet Juliane Marie Centret, Kolding Sygehus, Herlev Hospital, Hvidovre University Hospital, North Zealand's Hospital, Zealand University Hospital - Roskilde
Responsible party
Lise Krogh (Principal Investigator, University of Aarhus) — Principal investigator
First posted
Oct 27, 2020
Start date
Oct 19, 2020
Primary completion
Jul 10, 2026
Completion
Jul 29, 2026
Last update
Oct 20, 2026

Study contacts

Lise Q Krogh, MD
principal investigator · Aarhus University Hospital
Julie Glavind, MD, PhD
study chair · Aarhus University Hospital
Sidsel Boie, MD, PhD
study chair · Randers Regional Hospital
Jens Fuglsang, MD, PhD
study chair · Aarhus University Hospital
Tine B Henriksen, MD, PhD
study chair · Aarhus University Hospital
Jim Thornton, MD, PhD
study chair · Nottingham University
Katja A Taastrøm, Midwife, MSc
study chair · Aarhus University Hospital
Anne Cathrine M Kjeldsen, Midwife, MSc
study chair · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion